CY1122208T1 - Μεθοδος μετρονομικης χορηγησης προφαρμακων καπτοθεκινης (π.χ. peg-ιρινοτεκανης) - Google Patents
Μεθοδος μετρονομικης χορηγησης προφαρμακων καπτοθεκινης (π.χ. peg-ιρινοτεκανης)Info
- Publication number
- CY1122208T1 CY1122208T1 CY20191100970T CY191100970T CY1122208T1 CY 1122208 T1 CY1122208 T1 CY 1122208T1 CY 20191100970 T CY20191100970 T CY 20191100970T CY 191100970 T CY191100970 T CY 191100970T CY 1122208 T1 CY1122208 T1 CY 1122208T1
- Authority
- CY
- Cyprus
- Prior art keywords
- captothekin
- irinotecan
- prodrugs
- peg
- metronomic administration
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 229960004768 irinotecan Drugs 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9951608P | 2008-09-23 | 2008-09-23 | |
| US10693108P | 2008-10-20 | 2008-10-20 | |
| US17343309P | 2009-04-28 | 2009-04-28 | |
| PCT/US2009/005284 WO2010036335A1 (en) | 2008-09-23 | 2009-09-23 | Compositions and methods for achieving sustained therapeutic drug concentrations in a subject |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122208T1 true CY1122208T1 (el) | 2020-11-25 |
Family
ID=41268391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100970T CY1122208T1 (el) | 2008-09-23 | 2019-09-17 | Μεθοδος μετρονομικης χορηγησης προφαρμακων καπτοθεκινης (π.χ. peg-ιρινοτεκανης) |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8906353B2 (enExample) |
| EP (1) | EP2349346B1 (enExample) |
| JP (3) | JP2012503602A (enExample) |
| KR (1) | KR20110063457A (enExample) |
| CN (1) | CN102164617A (enExample) |
| AU (1) | AU2009297091B2 (enExample) |
| CA (1) | CA2736939C (enExample) |
| CY (1) | CY1122208T1 (enExample) |
| DK (1) | DK2349346T3 (enExample) |
| ES (1) | ES2744975T3 (enExample) |
| HR (1) | HRP20192120T1 (enExample) |
| HU (1) | HUE047352T2 (enExample) |
| IL (1) | IL211888A (enExample) |
| LT (1) | LT2349346T (enExample) |
| MX (1) | MX2011003063A (enExample) |
| PL (1) | PL2349346T3 (enExample) |
| PT (1) | PT2349346T (enExample) |
| RS (1) | RS59607B1 (enExample) |
| SI (1) | SI2349346T1 (enExample) |
| SM (1) | SMT201900609T1 (enExample) |
| WO (1) | WO2010036335A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2349346T (pt) | 2008-09-23 | 2019-10-24 | Nektar Therapeutics | Método de dosagem metronómica com profármacos de camptotecina (e.g. peg-irinotecano). |
| ES2779225T3 (es) * | 2011-04-08 | 2020-08-14 | Sphaera Pharma Pte Ltd | Reactivos de merilformilo sustituido y procedimiento de uso de los mismos para modificar propiedades fisicoquímicas y/o farmacocinéticas de compuestos |
| CN104813167B (zh) * | 2012-11-28 | 2019-04-09 | 尼克塔治疗公司 | 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法 |
| EP3258913A1 (en) * | 2015-02-17 | 2017-12-27 | Mallinckrodt Nuclear Medicine LLC | Modified docetaxel liposome formulations and uses thereof |
| EP3463298B1 (en) | 2016-06-02 | 2021-09-01 | Innopharmax, Inc. | Metronomic oral gemcitabine for cancer therapy |
| CN106539557A (zh) * | 2016-10-08 | 2017-03-29 | 西安交通大学 | 一种基于恒速静脉输入的药代动力学参数的测定方法 |
| CN112996533B (zh) | 2018-09-17 | 2025-01-10 | 费城儿童医院 | 基于聚合物的大分子前药 |
| CA3209512A1 (en) * | 2021-02-23 | 2022-09-01 | Edison Oncology | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases |
| CN115317486B (zh) * | 2022-08-17 | 2024-04-19 | 南昌大学 | 一种共载紫杉醇和伊立替康前药纳米制剂及其制备方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4406793A (en) | 1992-06-04 | 1993-12-30 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
| US5614549A (en) | 1992-08-21 | 1997-03-25 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5840900A (en) | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5965566A (en) | 1993-10-20 | 1999-10-12 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5605976A (en) | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
| IL117684A (en) | 1995-04-07 | 2002-02-10 | Pharmacia & Upjohn Inc | Intermediates and Process for Production of History of Kempotocin (CPT-11) and Related Compounds |
| US5726181A (en) | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
| SG50747A1 (en) | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| JP3737518B2 (ja) | 1996-03-12 | 2006-01-18 | ピージー−ティーエックスエル カンパニー， エル．ピー． | 水溶性パクリタキセルプロドラッグ |
| US6011042A (en) | 1997-10-10 | 2000-01-04 | Enzon, Inc. | Acyl polymeric derivatives of aromatic hydroxyl-containing compounds |
| US6111107A (en) | 1997-11-20 | 2000-08-29 | Enzon, Inc. | High yield method for stereoselective acylation of tertiary alcohols |
| US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| WO2000064486A2 (en) | 1999-04-28 | 2000-11-02 | Vectramed, Inc. | Enzymatically activated polymeric drug conjugates |
| WO2000066125A1 (en) | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
| DE60026073T2 (de) | 1999-12-22 | 2006-09-28 | Nektar Therapeutics Al, Corp., Huntsville | Sterisch gehinderte derivate von wasserlöslichen polymeren |
| AU2001257577A1 (en) | 2000-02-28 | 2001-09-03 | Shearwater Corporation | Water-soluble polymer conjugates of artelinic acid |
| US6629995B1 (en) | 2000-03-31 | 2003-10-07 | Super Gen, Inc. | Camptothecin conjugates |
| MXPA03000481A (es) | 2000-07-21 | 2004-09-09 | Schlumberger Technology Bv | Metodos de resonancia magnetica nuclear para extraer informacion sobre un fluido en una formacion rocosa. |
| AU2002217981A1 (en) | 2000-11-30 | 2002-06-11 | Cornerstone Pharmaceuticals, Inc. | Water-soluble polymer conjugates of triazine derivatives |
| TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
| US7401013B2 (en) | 2001-10-15 | 2008-07-15 | Lockheed Martin Corporation | Method to optimize test data |
| KR20050040832A (ko) | 2001-10-29 | 2005-05-03 | 넥타르 테라퓨틱스 에이엘, 코포레이션 | 단백질 키나아제 ｃ 억제제의 중합체 공액 |
| JP2005507934A (ja) | 2001-10-30 | 2005-03-24 | ネクター セラピューティックス エイエル，コーポレイション | レチノイン酸の水溶性ポリマー結合体 |
| AU2002346686A1 (en) * | 2001-12-07 | 2003-06-23 | Intermune, Inc. | Compositions and method for treating hepatitis virus infection |
| US6608076B1 (en) | 2002-05-16 | 2003-08-19 | Enzon, Inc. | Camptothecin derivatives and polymeric conjugates thereof |
| US20040058981A1 (en) | 2002-06-06 | 2004-03-25 | University Of Washington | Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer |
| US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| ATE533513T1 (de) | 2002-09-06 | 2011-12-15 | Cerulean Pharma Inc | Polymere auf basis von cyclodextrin zur verabreichung von an diese kovalent gebundene arzneimittel |
| KR101200729B1 (ko) * | 2003-09-17 | 2012-11-13 | 넥타르 테라퓨틱스 | 다분지형 고분자 전구약물 |
| US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
| US7462627B2 (en) * | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| WO2007098091A2 (en) * | 2006-02-17 | 2007-08-30 | Novacea, Inc. | Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs |
| BRPI0807232A2 (pt) * | 2007-02-09 | 2014-04-29 | Enzon Pharmaceuticals Inc | Tratamento de cânceres resistentes ou refratários com conjugados poliméricos multi-braços de 7-etil-10-hidroxicamptotecina |
| CN101199857B (zh) | 2007-12-12 | 2011-04-13 | 中国药科大学 | mPEG-PLA-喜树碱类药物的结合物 |
| PT2349346T (pt) | 2008-09-23 | 2019-10-24 | Nektar Therapeutics | Método de dosagem metronómica com profármacos de camptotecina (e.g. peg-irinotecano). |
-
2009
- 2009-09-23 PT PT97893648T patent/PT2349346T/pt unknown
- 2009-09-23 KR KR1020117005982A patent/KR20110063457A/ko not_active Ceased
- 2009-09-23 HR HRP20192120TT patent/HRP20192120T1/hr unknown
- 2009-09-23 AU AU2009297091A patent/AU2009297091B2/en active Active
- 2009-09-23 SI SI200932010T patent/SI2349346T1/sl unknown
- 2009-09-23 LT LTEP09789364.8T patent/LT2349346T/lt unknown
- 2009-09-23 WO PCT/US2009/005284 patent/WO2010036335A1/en not_active Ceased
- 2009-09-23 US US13/120,551 patent/US8906353B2/en active Active
- 2009-09-23 HU HUE09789364A patent/HUE047352T2/hu unknown
- 2009-09-23 PL PL09789364T patent/PL2349346T3/pl unknown
- 2009-09-23 RS RS20191501A patent/RS59607B1/sr unknown
- 2009-09-23 CN CN2009801371326A patent/CN102164617A/zh active Pending
- 2009-09-23 DK DK09789364.8T patent/DK2349346T3/da active
- 2009-09-23 EP EP09789364.8A patent/EP2349346B1/en active Active
- 2009-09-23 MX MX2011003063A patent/MX2011003063A/es active IP Right Grant
- 2009-09-23 CA CA2736939A patent/CA2736939C/en active Active
- 2009-09-23 ES ES09789364T patent/ES2744975T3/es active Active
- 2009-09-23 JP JP2011527834A patent/JP2012503602A/ja not_active Withdrawn
- 2009-09-23 SM SM20190609T patent/SMT201900609T1/it unknown
-
2011
- 2011-03-23 IL IL211888A patent/IL211888A/en active IP Right Grant
-
2014
- 2014-11-17 JP JP2014232556A patent/JP6076317B2/ja active Active
- 2014-11-26 US US14/555,440 patent/US9801873B2/en active Active
-
2016
- 2016-09-26 JP JP2016186670A patent/JP2016216510A/ja not_active Withdrawn
-
2017
- 2017-10-03 US US15/723,981 patent/US10525051B2/en active Active
-
2019
- 2019-09-17 CY CY20191100970T patent/CY1122208T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009297091A1 (en) | 2010-04-01 |
| US8906353B2 (en) | 2014-12-09 |
| CA2736939C (en) | 2021-09-14 |
| KR20110063457A (ko) | 2011-06-10 |
| CN102164617A (zh) | 2011-08-24 |
| US9801873B2 (en) | 2017-10-31 |
| JP2012503602A (ja) | 2012-02-09 |
| PT2349346T (pt) | 2019-10-24 |
| IL211888A (en) | 2015-08-31 |
| JP2016216510A (ja) | 2016-12-22 |
| US10525051B2 (en) | 2020-01-07 |
| US20180028525A1 (en) | 2018-02-01 |
| HUE047352T2 (hu) | 2020-04-28 |
| US20150087668A1 (en) | 2015-03-26 |
| RS59607B1 (sr) | 2020-01-31 |
| CA2736939A1 (en) | 2010-04-01 |
| MX2011003063A (es) | 2011-04-21 |
| HRP20192120T1 (hr) | 2020-02-21 |
| SMT201900609T1 (it) | 2020-01-14 |
| JP2015034180A (ja) | 2015-02-19 |
| DK2349346T3 (da) | 2019-10-07 |
| EP2349346B1 (en) | 2019-08-28 |
| AU2009297091B2 (en) | 2015-03-05 |
| EP2349346A1 (en) | 2011-08-03 |
| JP6076317B2 (ja) | 2017-02-08 |
| IL211888A0 (en) | 2011-06-30 |
| WO2010036335A1 (en) | 2010-04-01 |
| LT2349346T (lt) | 2019-09-25 |
| PL2349346T3 (pl) | 2020-03-31 |
| SI2349346T1 (sl) | 2019-12-31 |
| ES2744975T3 (es) | 2020-02-27 |
| US20110269789A1 (en) | 2011-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122208T1 (el) | Μεθοδος μετρονομικης χορηγησης προφαρμακων καπτοθεκινης (π.χ. peg-ιρινοτεκανης) | |
| CY1119059T1 (el) | Χρηση προφαρμακων κανναβιδιολης σε τοπικη και διαδερμικη χορηγηση με μικροβελονες | |
| CY1126136T1 (el) | Μεθοδοι θεραπειας της αρθριτιδας | |
| CY1122687T1 (el) | Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συναρμογης σε ενα υποκειμενο | |
| SV2010003451A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| MX376937B (es) | Metodos para tratar cancer pancreático mediante el uso de terapias de combinacion que comprenden irinotecano liposómico. | |
| CY1112831T1 (el) | Παραγωγα αζαβιρηενυlαμινοβενζοιc acid σαν παραγοντες καταστολης dhodh | |
| UY31543A1 (es) | Sistema de administracion de rnai de interferencia y usos del mismo | |
| BR112013004698A2 (pt) | composições farmacêuticas compreendendo derivados de poh | |
| EA201690276A1 (ru) | Комбинированная терапия с применением пептид эпоксикетонов | |
| CR20120625A (es) | Métodos de tratamiento contra el cáncer pancreático | |
| GT200500155A (es) | Terapia del càncer resistente al platino | |
| CY1124890T1 (el) | Συστηματα και μεθοδοι χορηγησης φαρμακων για θεραπεια καρκινου της ουροδοχου κυστης που περιλαμβανουν οξαλιπλατινη | |
| DK3248600T3 (da) | Kombinationer og måder til administration af terapeutiske stoffer og kombinationsterapi | |
| AR088267A1 (es) | Derivados, de los factores de coagulacion sanguinea vii y viia, conjugados y complejos que comprenden a los mismos y sus usos | |
| WO2011163594A3 (en) | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives | |
| UY28923A1 (es) | Compuestos terapéuticos: piridina como estructura base | |
| CR11065A (es) | Administracion semanal de inhibidores de peptidasa de dipeptidilo | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| CR20130530A (es) | Derivados glucósidos y sus usos para el tratamiento de la diabetes | |
| MX2013008175A (es) | Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos. | |
| EA201391689A1 (ru) | Система доставки лекарственного средства | |
| MX2009011900A (es) | Curacion de herida diabetica. | |
| MX2013012206A (es) | Metodo para producir substancias con gas sobresaturado,dispositivo de suministro transdermico de las mismas, y usos de las mismas. | |
| UY31839A (es) | Compuestos |